Search. Learn. Save

Platform for Pharmaceutical Products for Healthcare Professionals
Search By
☰ Generic Formulas

Generic Formulas X

Lefamulin

Lefamulin: A New Era in Antibiotic Therapy

Introduction

In the ever-evolving battle against infectious diseases, the development of new antibiotics is a critical need, particularly given the rise of multidrug-resistant pathogens. Lefamulin represents one of the first new classes of antibiotics approved in nearly two decades. It offers an exciting option for treating community-acquired bacterial pneumonia (CABP) and potentially other serious bacterial infections.

Lefamulin

Lefamulin is a semi-synthetic pleuromutilin antibiotic. It’s the first systemic pleuromutilin approved for human use in the United States. Traditionally, pleuromutilins were primarily used in veterinary medicine, but the advent of lefamulin represents a significant advancement in human antibacterial therapy. The U.S. Food and Drug Administration (FDA) approved lefamulin in August 2019 for the treatment of adults with community-acquired bacterial pneumonia (CABP). Marketed under the brand name Xenleta, it is available in both oral and intravenous (IV) formulations.

Mechanism of Action

Lefamulin exerts its antibacterial effects by:

  • Inhibiting bacterial protein synthesis.

  • Binding to the peptidyl transferase center (PTC) of the 23S rRNA of the 50S ribosomal subunit.

  • Preventing the correct positioning of tRNA, thus blocking the formation of peptide bonds necessary for protein elongation.

This unique binding site is distinct from that targeted by macrolides, tetracyclines, or other classes, making cross-resistance unlikely.

Thus, lefamulin offers an effective option against some strains resistant to older antibiotics.

Spectrum of Activity

Lefamulin displays broad-spectrum activity, particularly against:

  • Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA).

  • Atypical pathogens such as Mycoplasma pneumoniae, Chlamydophila pneumoniae, and Legionella pneumophila.

  • Some Gram-negative bacteria, though its Gram-negative coverage is more limited.

This broad activity makes it ideal for treating pneumonia caused by multiple potential pathogens.

Indications

Currently, the primary FDA-approved indication for lefamulin is:

1. Community-Acquired Bacterial Pneumonia (CABP)

Lefamulin is indicated for adults with CABP caused by susceptible microorganisms. CABP remains a significant cause of morbidity and mortality globally, especially among older adults and individuals with comorbid conditions.

Potential future indications under research include:

  • Skin and soft tissue infections (SSTIs).

  • Sexually transmitted infections (like gonorrhea).

  • Complicated bacterial infections.

Its unique properties suggest a broad utility beyond pneumonia.

Dosing and Administration

IV Administration

  • 150 mg IV over 60 minutes every 12 hours for 5 to 7 days.

Oral Administration

  • 600 mg orally every 12 hours for 5 days.

Transition from IV to oral therapy is possible based on clinical improvement, providing flexibility for outpatient treatment.

Important Considerations

  • Oral lefamulin should be taken at least 1 hour before or 2 hours after a meal.

  • IV administration requires a dedicated line or flushing due to potential compatibility issues with other IV drugs.

Clinical Trials Supporting Approval

Two pivotal trials led to FDA approval:

LEAP 1 (Lefamulin Evaluation Against Pneumonia 1)

  • Compared lefamulin IV/oral therapy to moxifloxacin (with or without linezolid) in hospitalized adults.

  • Showed non-inferiority to moxifloxacin in early clinical response and overall outcomes.

  • Highlighted lefamulin’s effectiveness even in patients with significant comorbidities.

LEAP 2

  • Evaluated oral lefamulin against oral moxifloxacin in adults with CABP.

  • Demonstrated comparable efficacy with a shorter 5-day course (vs. 7 days for moxifloxacin).

  • Confirmed excellent tolerability.

Together, these trials established lefamulin as a strong alternative to existing CABP treatments.

Benefits of Lefamulin

1. New Mechanism

  • No cross-resistance with other common antibiotic classes.

2. Activity Against Resistant Pathogens

  • Effective against MRSA and drug-resistant Streptococcus pneumoniae.

3. Dual IV and Oral Formulations

  • Facilitates seamless hospital-to-home transitions.

4. Shorter Treatment Course

  • Only 5 days required, which may improve adherence.

5. Well-Tolerated

  • Lower rates of Clostridioides difficile infections compared to other antibiotics.

Side Effects

Like all medications, lefamulin carries potential side effects, although it is generally well tolerated.

Common Side Effects

  • Diarrhea

  • Nausea

  • Vomiting

  • Elevated liver enzymes

  • Hypokalemia

Serious Side Effects

  • QT interval prolongation: Caution is needed in patients with preexisting heart conditions or those on other QT-prolonging drugs.

  • Hypersensitivity reactions: Rare but possible.

Patients should be monitored for these effects, especially if taking medications with overlapping toxicity profiles.

Warnings and Precautions

  • QT Prolongation: Avoid in patients with known QT prolongation or taking other QT-prolonging drugs.

  • Hypersensitivity: Stop treatment immediately if allergic reactions occur.

  • Liver Impairment: Use caution in patients with severe hepatic impairment.

  • Pregnancy: Lefamulin may cause fetal harm. It is classified as pregnancy category warning based on animal studies.

Clinicians should thoroughly evaluate patients’ health status and concurrent medications before prescribing lefamulin.

Drug Interactions

  • Lefamulin is metabolized primarily by CYP3A4.

  • CYP3A4 inhibitors (e.g., ketoconazole) can increase lefamulin levels, raising toxicity risks.

  • CYP3A4 inducers (e.g., rifampin) can decrease lefamulin levels, potentially reducing efficacy.

  • Co-administration with QT-prolonging agents (e.g., amiodarone) should be avoided.

Checking a patient’s medication list for potential interactions is critical before starting therapy.

Use in Special Populations

Pregnancy

  • Animal studies showed adverse fetal outcomes.

  • Lefamulin should be used during pregnancy only if the potential benefit justifies the potential risk.

Breastfeeding

  • It is unknown whether lefamulin is excreted in human milk.

  • Women should be advised to either discontinue breastfeeding or the drug.

Geriatric Use

  • No overall differences in safety or effectiveness were observed between older and younger patients.

How Lefamulin Compares to Other Antibiotics for CABP

Antibiotic Route Typical Duration MRSA Coverage Atypical Coverage QT Risk
Lefamulin IV/Oral 5 days Yes Yes Yes
Moxifloxacin (fluoroquinolone) IV/Oral 7-10 days No Yes Yes
Azithromycin (macrolide) Oral/IV 5 days No Yes Minor
Ceftriaxone + Azithromycin IV 5-7 days No Yes (via azithro) Minor

Lefamulin offers advantages of short-course therapy, oral option, MRSA coverage, and less broad disruption of gut flora compared to fluoroquinolones.

Emerging Research and Future Uses

Researchers are actively studying lefamulin for:

  • Complicated skin and soft tissue infections (cSSTIs).

  • Drug-resistant sexually transmitted infections, such as gonorrhea.

  • Hospital-acquired pneumonia and ventilator-associated pneumonia (HAP/VAP).

Its novel mechanism and favorable safety profile position lefamulin as a potential key player in these areas, pending successful clinical trials.

Challenges and Limitations

While lefamulin is a significant addition to antibiotic therapy, there are limitations:

  • Cost: Lefamulin is expensive compared to generic options like azithromycin or doxycycline.

  • Limited Gram-negative coverage: Not ideal as monotherapy for infections with Gram-negative organisms.

  • QT prolongation: A concerning side effect in vulnerable patients.

  • Narrow indication: Currently approved only for CABP.

Ongoing research aims to expand its approved indications and solidify its role.

Patient Counseling Points

  • Take lefamulin exactly as prescribed, and complete the entire course.

  • Oral lefamulin must be taken on an empty stomach (1 hour before or 2 hours after meals).

  • Notify healthcare providers of any medications being taken, especially heart medications.

  • Report symptoms such as irregular heartbeat, fainting, or severe diarrhea immediately.

  • Discuss potential pregnancy risks with healthcare providers if applicable.

Educating patients increases adherence and ensures early detection of potential adverse effects.

Conclusion

Lefamulin marks a welcome advancement in the treatment of community-acquired bacterial pneumonia, providing physicians with a much-needed option amid rising antibiotic resistance. Its novel mechanism, broad-spectrum activity, dual formulation (IV and oral), and short treatment duration offer clear benefits to patients. However, clinicians must be mindful of its side effect profile, particularly concerning QT prolongation and potential drug interactions. As research continues to explore wider applications for lefamulin, it could soon become an even more versatile tool in the infectious disease arsenal.